Symbols

LCTX

Lineage Cell·AMEX

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 0

Stock Price Surged Significantly

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LCTX

Lineage Cell Therapeutics, Inc.

A biotechnology company that develops and commercializes cellular therapies for cancer and immune system disorders

Industry

Biological Technology

Established Date

11/30/1990

Listing Date

10/30/2009

Exchange

American Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.lineagecell.com

Security Type

Common stock

Office address

2173 Salk Avenue, Suite 200, Carlsbad, California 92008

Business

A biotechnology company focused on the emerging field of regenerative medicine.

Introduction

Lineage Cell Therapeutics, Inc., was incorporated in California on November 30, 1990. The company is a clinical-stage biotechnology company focused on developing allogeneic cell replacement therapies to treat serious diseases caused by cell loss or dysfunction. Its method utilizes a proprietary manufacturing platform to produce mature differentiated cells for a variety of indications.

Company Financials

EPS

LCTX has released its 2025 Q4 earnings. EPS was reported at 0, versus the expected -0.05, beating expectations. The chart below visualizes how LCTX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LCTX has released its 2025 Q4 earnings report, with revenue of 6.61M, reflecting a YoY change of 130.40%, and net profit of 892.00K, showing a YoY change of 127.45%. The Sankey diagram below clearly presents LCTX's revenue sources and cost distribution.